LLY vs ABBV: Eli Lilly vs AbbVie Business Model Comparison

Most investors treat big pharma as a defensive sector. People get sick in recessions too, so drug sales should hold up no matter what. The demand part is true. The durability part is not, because every drug company's best products come with an expiry date written into law.

A patent gives a company roughly 20 years of protection from the filing date, and much of that time gets used up in clinical trials before the drug ever reaches a pharmacy. When protection ends, generics or biosimilars arrive and prices fall hard. A pharmaceutical company is never just running a business. It's running a business that has to rebuild itself every decade or so.

Eli Lilly (NYSE: LLY) and AbbVie (NYSE: ABBV) show two very different points in that cycle.

Lilly was founded in 1876 and is now driven mainly by diabetes and obesity medicines. Mounjaro treats type 2 diabetes. Zepbound treats obesity and related conditions. It also sells Verzenio in oncology and Taltz in immunology, but the growth story is the first two.

AbbVie is much younger. It was spun off from Abbott in 2013, and its portfolio spans immunology, neuroscience, oncology and aesthetics. The names include Skyrizi, Rinvoq, Botox, Vraylar and Venclexta. Its 2020 acquisition of Allergan brought in Botox and most of the aesthetics business.

Both companies depend on the same things: intellectual property, clinical evidence, regulatory approval and continuous research. The difference is where each one sits on the clock. Lilly is early in the protected life of its biggest product. AbbVie has already lived through losing its biggest product and come out the other side.

Drug names mean nothing to most investors, and they shouldn't have to. Here's what each one is in plain terms.

Lilly's main products:

→ Mounjaro and Zepbound (tirzepatide): the weekly injection behind most of the weight-loss drug headlines. It belongs to the GLP-1 family, the same group as Novo Nordisk's Ozempic and Wegovy. Mounjaro is the version approved for type 2 diabetes. Zepbound is the same drug approved for weight loss.
→ Verzenio: a daily pill for a common type of breast cancer.
→ Taltz: an injection for psoriasis and related joint and spine inflammation.
→ Retatrutide: not on the market yet. It's Lilly's next-generation weight-loss drug, still in clinical trials, and the most likely successor to tirzepatide.

AbbVie's main products:

→ Humira: the old blockbuster. An injection for autoimmune conditions like rheumatoid arthritis, Crohn's disease and psoriasis. Cheaper copies (biosimilars) have been eating its sales since 2023.
→ Skyrizi: an injection for psoriasis, Crohn's disease and ulcerative colitis. One of Humira's two replacements.
→ Rinvoq: a daily pill for rheumatoid arthritis, eczema and inflammatory bowel disease. The other Humira replacement.
→ Botox: the same product sold two ways. Botox Therapeutic treats chronic migraines and muscle spasms. Botox Cosmetic smooths wrinkles.
→ Vraylar: a pill for schizophrenia and bipolar disorder, also used alongside antidepressants.
→ Venclexta: a pill for certain leukemias.
→ Qulipta: a daily pill to prevent migraines.
→ Juvederm: cosmetic fillers for lips and cheeks.

Two things stand out. Lilly's growth comes from one drug aimed at one of the largest health problems in the world. AbbVie's sales come from treatments for long-term conditions, plus a cosmetics business that has nothing to do with insurance coverage. Lilly is early in the protected life of its biggest product. AbbVie has already lived through losing its biggest product and come out the other side.

​Humira was the best-selling drug in the world for most of the decade before its U.S. patent protection ended, with annual sales peaking above $20B. AbbVie spent years preparing for its decline, which is a big part of why Skyrizi and Rinvoq were ready when biosimilars arrived.

Buying a stock is easy. Finding one you may never need to sell is harder.

This free report reveals seven blue-chip companies selected for financial strength, durable demand and long-term potential to hold up when markets turn ugly.

View the Free Report

Lilly's 2025 numbers are hard to ignore.

A company with $65 billion in sales grew 45% in one year. That doesn't happen in large-cap pharma. And it kept going: in Q2 2026, Lilly reported $23.0 billion in quarterly revenue, up 48% year over year, against AbbVie's $17.0 billion, up 10.2%.

This is the detail that changes the picture. Mounjaro and Zepbound are not two products. They're two brand names for the same active molecule, tirzepatide. That means 56% of Lilly's revenue rests on one ingredient. If a competitor beats it, if insurers push the price down, or if a safety issue appears, both brands take the hit at the same time.

The math is simple. Say tirzepatide revenue fell 20% in some future year. With 56% of the company riding on it, that alone would cut total revenue by about 11%, before counting anything else. That's an illustration, not a forecast, but it shows how much weight one molecule is carrying.

AbbVie's top two products account for 42% of revenue, which is still a lot. The difference is that Skyrizi and Rinvoq are separate medicines with separate mechanisms. A problem with one doesn't automatically become a problem with the other. Concentration risk works the same way inside a company as it does in a portfolio without enough diversification: the number of names matters less than how many of them can fail for the same reason.

Humira was AbbVie's company-defining drug. It faced U.S. biosimilar competition starting in 2023, and that's exactly the moment that has broken drug companies before. Revenue from the best-selling product falls off quickly, and if nothing is ready to replace it, the whole business shrinks.

AbbVie had something ready. Skyrizi and Rinvoq, both immunology treatments aimed at many of the same conditions, generated about $25.9 billion together in 2025. Humira brought in about $4.5 billion. The replacement now earns more than five times what the original drug does.

This is the most useful piece of evidence in the whole comparison. It proves AbbVie can do the hardest thing a drug company has to do, which is hand its revenue from one generation of products to the next without the business collapsing in between. It doesn't prove AbbVie will do it again. Every future patent expiry is a fresh test.

Lilly hasn't faced that test with tirzepatide yet. It will. Competition, pricing pressure and eventual loss of exclusivity are coming, the same way they came for Humira. Lilly's pipeline, including retatrutide, is partly designed to extend its lead before that happens. Whether it works is a question for the next decade, not this one.

That's the same lesson as the myth of forever dividend stocks. A great product can look permanent while it's growing. In pharma, you know in advance that it isn't.

Revenue isn't cash. The cash flow numbers flip the picture.

AbbVie generated $2.2 billion more operating cash flow on $4 billion less revenue. Part of the gap is that Lilly is spending heavily to build the factories it needs to meet obesity-drug demand. It spent $7.8 billion on capital expenditures in 2025, and that money has to come from somewhere.

This doesn't make Lilly inefficient. It's a company in build mode, and building capacity now is what lets it sell more later. The risk is that the spending is a bet on demand staying high. If competitors catch up or prices drop faster than expected, Lilly ends up with expensive factories earning lower returns than planned.

AbbVie is in a different mode. It spreads its cash across research, acquisitions, debt repayment and a dividend that income investors rely on. That's a mature company managing a portfolio, not one racing to keep up with orders.

In the Caterpillar and Fastenal comparison, both moats could last as long as the companies kept executing. A distributor's branch network or a dealer's service relationships don't expire on a fixed date.

A drug patent does.

Both companies have real advantages. Chronic conditions mean patients stay on treatment for years, which creates repeat demand. Research capability and regulatory experience are hard to replicate. But neither company can stand still on the products it has today.

The way I'd frame it: Lilly's moat is currently the stronger asset, and AbbVie's is the more proven process.

None of these are hypothetical risks invented to balance the page. They're the normal operating conditions of the industry. A strong management team understands that and strategically work and plans for these challenges.

Lilly asks you to decide how long exceptional growth can last and how much of it is already in the price. AbbVie asks you to decide whether its pipeline and acquisitions can keep profits, cash flow and the dividend going as older drugs fade. Those are different questions, and neither one gets answered by the revenue growth rate.

A stock growing 45% a year usually carries a price that assumes it keeps growing fast for a long time. If growth slows from 45% to 15%, the business is still excellent and the stock can still fall. That's why the price you pay at the start shapes your return as much as the company does.

For AbbVie, the dividend gives you a cleaner way to check the price. Compare the current yield to its own five- or ten-year average, and pair it with dividend growth using something like the Chowder Rule. Lilly's yield is too low for that to tell you much. You're buying it for growth, and valuation has to come from earnings and free cash flow instead.

For Canadians holding either one, account choice matters. U.S. dividends in a TFSA lose 15% to withholding tax that you can't recover. In an RRSP, the treaty exempts them. That makes little difference for Lilly's small dividend and a real one for AbbVie, which is covered in more detail in the Canadian investment income tax guide.

On business model alone, AbbVie. It has already done the thing every drug company eventually has to do, and its revenue is spread across more products that don't fail together. It produces more cash from less revenue and pays a meaningful part of it out.

Lilly is the more exciting business right now, and it may well turn out to be the better stock. It has a leading position in one of the largest new drug markets in decades. But it's asking investors to pay for growth that rests on one molecule, with a patent clock that has already started. The question isn't whether tirzepatide is a great drug. It's what Lilly looks like after it.

Choosing between the stocks still takes the full checklist: free cash flow, debt, dividend coverage and current valuation, the same work that shows up across the businesses superinvestors hold for decades. The business comparison only tells you what you'd be buying.

In pharma, the next product matters more than the current one.

Inner Circle members see every holding, allocation change, and trade I make. Every month!